Gadofosveset Trisodium for Heart Imaging Studies
A Pilot Dosing Study for Gadofosveset Trisodium (Ablavar) for Coronary Magnetic Resonance Angiography (MRA)
Background:
- Magnetic resonance imaging (MRI) is type of imaging study that uses magnetic fields and radio waves to take pictures of the body. To help the images show up more clearly, a contrast agent is injected into a vein. Researchers are interested in finding contrast agents that can help show problems with the blood vessels around the heart. They want to test an agent called Gadofosveset Trisodium to see how it works in MRI scans.
Objectives:
- To test the effectiveness of Gadofosveset Trisodium as a contrast agent in heart MRI scans.
Eligibility:
- Healthy volunteers between 18 and 45 years of age.
Design:
- Participants will be screened with a physical exam and medical history. They will provide blood samples before the scanning sessions.
- Participants will have an MRI scan after the screening visit. They will have a dose of the contrast scan before the study.
- Participants will return for one additional MRI scan within 1 to 2 months of each scan. Different doses of the contrast agent will be used for each scan.
- An additional blood sample will be collected within 1 week of the second MRI scan.
調査の概要
状態
詳細な説明
The purpose of this study is to determine if the diagnostic quality of contrast-enhanced coronary magnetic resonance angiography (MRA) is improved by using a higher versus a lower dose of a gadolinium-based contrast agent. We will compare two doses of an intravascular contrast agent (Gadofosveset, 0.03 and 0.06 mmol/kg) in this pilot dosing study. Healthy participants will be recruited who do not have a clinical indication for MR angiography but do have safety clearance for IV gadolinium contrast and MR scanning.
Subjects will be evaluated in order to determine if the signal to noise ratio (SNR) and contrast to noise ratio (CNR) of the coronary arteries is increased for the higher dose contrast agent. Parameters will be compared with paired t-testing for significance.
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
Maryland
-
Bethesda、Maryland、アメリカ、20892
- National Institutes of Health Clinical Center, 9000 Rockville Pike
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
- INCLUSION CRITERIA:
A. Able to understand and sign informed consent.
B. Able to complete an MRI scan.
C. Age 18-45 years old.
D. eGFR greater than or equal to 60mL/min/1.73m(2) within 1 week prior to gadolinium injection.
E. NIH employees may be involved and NIH requirements will be followed as laid out in NIH Policy Manual 2300-630-3 - Leave Policy for NIH Employees Participating in NIH Medical Research Studies.
F. Willing to travel to the NIH for scheduled follow-up visits and scans as well as potential repeat scans in the event of sub-optimal scanning.
EXCLUSION CRITERIA:
Individuals will be excluded from the study if they have:
A. Contra-indications to undergoing a MRA
Please review Radiology MRI section MRI safety questionnaire.
B. MRI with contrast within the last 6 months (self-reported) outside of our protocol.
C. Contra indications to receiving gadolinium-based contrast agent (specified here and on MRI safety questionnaire):
- Allergy to gadolinium-based contrast
- Labs:
i. Kidney and liver function above the upper limits of normal
ii. eGFR < 60ml/min/1.73m(2)
iii. Pregnancy test: positive
c. Acute renal failure, renal transplantation, curent dialysis treatment or hepatorenal syndrome
d. History of liver transplantation or severe liver disease
e. Severe Asthma
f. Hemoglobinopathies
g. History of multiple myeloma
h. History of significant allergic reaction to gadolinium-based contrast agents
i. Evaluated to be at increased risk for Nephrogenic Systemic Fibrosis (NSF).
D. Current written (or self-reported) record of:
- atrial fibrillation
- cardiac surgery
- cancer treatment
- other comorbid conditions that otherwise indicates the participant has renal function that may deteriorate between study procedures due to the participant s underlying medical condition or that would not allow the study subject to complete the protocol.
E. Current written (or self-reported) record of active:
- Clinically diagnosed angina, heart failure, and/or clinically significant electrical conduction abnormality in the heart.
- Pregnancy or lactation
- Mental, neurologic or social condition preventing understanding of the rationale, procedures, risks and potential benefits associated with the trial
- Paralyzed hemidiaphragm
- Over 400 lbs and/or a body circumference that prevents adequate MRI gantry insertion.
- Unable to lay flat in the scanner
- Claustrophobia otherwise requiring anesthesia or sedation to undergo MRI.
- Participant is not able to undergo intravenous line placement and/or refuse gadolinium contrast.
F. Any other conditions that precludes safety for MRI per the researcher s evaluation.
研究計画
研究はどのように設計されていますか?
デザインの詳細
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
---|---|
To evaluate 0.06 mmol/kg Gadofosveset trisodium compared to 0.03 mmol/kg Gadofosveset trisodium for the diagnostic quality of MRA of the coronary arteries, as measured by changes in signal to noise & contrast to noise ratios.
時間枠:18 months
|
18 months
|
協力者と研究者
捜査官
- 主任研究者:David A Bluemke, M.D.、National Institutes of Health Clinical Center (CC)
出版物と役立つリンク
一般刊行物
- Brenner DJ, Hall EJ. Computed tomography--an increasing source of radiation exposure. N Engl J Med. 2007 Nov 29;357(22):2277-84. doi: 10.1056/NEJMra072149. No abstract available.
- Rhee CM, Bhan I, Alexander EK, Brunelli SM. Association between iodinated contrast media exposure and incident hyperthyroidism and hypothyroidism. Arch Intern Med. 2012 Jan 23;172(2):153-9. doi: 10.1001/archinternmed.2011.677.
- Gerber TC, Carr JJ, Arai AE, Dixon RL, Ferrari VA, Gomes AS, Heller GV, McCollough CH, McNitt-Gray MF, Mettler FA, Mieres JH, Morin RL, Yester MV. Ionizing radiation in cardiac imaging: a science advisory from the American Heart Association Committee on Cardiac Imaging of the Council on Clinical Cardiology and Committee on Cardiovascular Imaging and Intervention of the Council on Cardiovascular Radiology and Intervention. Circulation. 2009 Feb 24;119(7):1056-65. doi: 10.1161/CIRCULATIONAHA.108.191650. Epub 2009 Feb 2. No abstract available.
- Ahlman MA, Raman FS, Pang J, Zemrak F, Sandfort V, Penzak SR, Fan Z, Liu S, Li D, Bluemke DA. Part 2 - Coronary angiography with gadofosveset trisodium: a prospective intra-subject comparison for dose optimization for 100 % efficiency imaging. BMC Cardiovasc Disord. 2016 Mar 22;16:58. doi: 10.1186/s12872-015-0152-8.
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。